A Peter Mac-led study has shown many Australian women at increased risk of breast cancer are unaware they can reduce their risk with medication.
More than 720 women and 220 of their clinicians responded to a survey assessing awareness of preventive medications, such as tamoxifen, that can reduce breast cancer risk.
These drugs are off-patent and so are not a focus of pharmaceutical companies when it comes to medications they support with patient and clinician awareness campaigns.
The surveyed women were all part of the ongoing kConFab study of families with strong history of breast and ovarian cancer.
Just ten (1.4%) of the women had ever taken preventive medication to reduce their risk of breast cancer and half (52%) were unaware this was available – along with 3% of breast surgeons and 35% of family doctors.
Among those who were aware, concern about side-effects (31%) and inadequate information (23%) were the main reasons women did not take preventive medication.
Dr Courtney Macdonald said for family doctors surveyed, the main barrier was insufficient knowledge about these medicines.
“When taken preventively, tamoxifen is generally well-tolerated and side-effects tend to be overestimated by women and doctors,” she also said.
An online tool – iPrevent – is available to help women and clinicians understand if preventive medications are appropriate and provide clear information on side-effects and benefits.
Dr Macdonald is lead author of a paper reporting these findings, published as a “must read” of 2021 in the journal Cancer Prevention Research with an accompanying editorial.
For more information contact the Peter Mac Communications team on 0417 123 048.
About Peter Mac
Peter MacCallum Cancer Centre is a world-leading cancer research, education and treatment centre and Australia’s only public health service solely dedicated to caring for people affected by cancer.
Story Source: Peter MacCallum Cancer Centre